December 9, 2025
hNPC01 Fast Track Designation by FDA
As the project partner, BLA congratulates Hopstem Therapeutics on receiving FDA Fast Track Designation for hNPC01 injection– the global first-in-class allogeneic human forebrain neural progenitor cell therapy Gaithersburg, MD (December 3, 2025) – BLA Regulatory LLC announced that, as a partner of Hopstem Therapeutics, it has successfully supported hNPC01 injection– the global first-in-class allogeneic human […]
hNPC01 Fast Track Designation by FDA
As the project partner, BLA congratulates Hopstem Therapeutics on receiving FDA Fast Track Designation for hNPC01 injection– the global first-in-class...